FDA Getting More Muscle to Take Unproven AA Drugs Off the Market
Created in 1982 in response to the HIV/AIDS epidemic, the U.S. Food and Drug Administration’s (FDA’s) Accelerated Approval (AA) Program provides for expedited approval of novel treatments of serious health conditions that the current market isn’t adequately serving....
Congress Looks to Beef up Agency’s Power to Withdraw Unproven AA Drugs
The House Energy and Commerce Committee is considering a pair of rival bills, one Democratic and one Republican, to reform the AA process.
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Thermo and Symphogen Aim to Boost Biopharma Discovery
SAN JOSE, CA — On March 1, Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company Servier, announce the continuation of their collaboration to...
Biopharma M&A Expected to Rebound After Sluggish 2021
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here